Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events | Zendy

Yan Xie | Zendy; Benjamin Bowe | Zendy; Andrew K. Gibson | Zendy; Janet B. McGill | Zendy; Ying Yan | Zendy; Geetha Maddukuri | Zendy; Ziyad AlAly | Zendy

Open Access

Comparative Effectiveness of the Sodium–Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events

Author(s) -

Yan Xie,

Benjamin Bowe,

Andrew K. Gibson,

Janet B. McGill,

Ying Yan,

Geetha Maddukuri,

Ziyad AlAly

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc20-1231

Subject(s) - empagliflozin , medicine , benzhydryl compounds , adverse effect , diabetes mellitus , canagliflozin , cotransporter , type 2 diabetes , sodium , pharmacology , endocrinology , chemistry , organic chemistry , bisphenol a , epoxy

To examine the comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin and other non-SGLT2i antihyperglycemics on the risk of major adverse kidney events (MAKE) of estimated glomerular filtration rate (eGFR) decline >50%, end-stage kidney disease, or all-cause mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research